Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|February 18, 2017
Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK CellsJérôme Rey, Cyril Fauriat, Eloïse Kochbati, et al.
Frontiers in Immunology|November 24, 2015
Increased NK Cell Maturation in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Samuel Granjeaud, Françoise Gondois-Rey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2015
Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcomeCaroline Pical-Izard, Roberto Crocchiolo, Samuel Granjeaud, et al.
Frontiers in Immunology|June 28, 2019
Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast CancerEsma Karkeni, Stéphanie O Morin, Berna Bou Tayeh, et al.
Blood|January 26, 2010
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantationAndreas T Björklund, Marie Schaffer, Cyril Fauriat, et al.
Cancers|June 2, 2021
Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling DonorRaynier Devillier, Boris Calmels, Sophie Guia, et al.
The Journal of Experimental Medicine|December 22, 2010
Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirusNiklas K Björkström, Therese Lindgren, Malin Stoltz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2008
Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotypeCyril Fauriat, Sandra Andersson, Andreas T Björklund, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2008
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapyKarl-Johan Malmberg, Yenan T Bryceson, Mattias Carlsten, et al.
Journal of Clinical Immunology|February 10, 2012
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapyCaroline Veuillen, Thérèse Aurran-Schleinitz, Rémy Castellano, et al.
Pageof 5